Rozrolimupab: Final Phase II data

Final data from a dose-escalation, open-label, international Phase II trial in 61 Rhesus D (RhD)-positive, non-splenectomized patients

Read the full 179 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE